We’re continually expanding our portfolio of advanced medicines
Lead asset and pipeline
Serplulimab is a novel, fully humanized anti–PD-1 IgG4 monoclonal antibody currently being evaluated in combination with chemotherapy in the US through a confirmatory bridging study for the treatment of extensive-stage small cell lung cancer (ES-SCLC). It has received orphan drug designation from both the FDA and the European Commission. The Committee for Medicinal Products for Human Use (CHMP) in Europe has also issued a positive opinion, recommending marketing authorization for the treatment. Download more information about serplulimab to learn more:
With respective opportunities associated with and held by our affiliates, the pipeline encompasses assets in oncology as well as in Immunology and glaucoma.
Our clinical trials validate serplulimab as our lead asset for the treatment of ES-SCLC. ASTRUM-005 is a study with positive results that showed significant improvement compared to chemotherapy and had unprecedented mOS of 15.8 months. Fosun has initiated the ASTRIDE trial to confirm the results of ASTRUM-005 to patients with ES-SCLC in the United States.
Highlights of our capabilities, with respective opportunities associated and held by our affiliates:
